The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
复制标题
DOI：
10.5812/ijem.40614
复制
发表时间：
2017-01
影响因子：
2.1
通讯作者：
Javanbakht MH
中科院分区：
文献类型：
--
作者：
Ansari S;Djalali M;Mohammadzadeh Honarvar N;Mazaherioun M;Zarei M;Agh F;Gholampour Z;Javanbakht MH
糖尿病是指血糖高于正常范围的一组代谢性疾病。此外，n-3多不饱和脂肪酸是调节人体机能活动所必需的。N-3多不饱和脂肪酸对糖尿病的影响已经在动物实验中进行了研究，但到目前为止，确切的量还没有确定。虹膜蛋白作为一种新的肌细胞因子，由骨骼肌释放，由于缺乏运动、超重和肥胖导致其水平降低。此外，血清淫羊藿素水平的降低与胰岛素抵抗和2型糖尿病的发生有关。本研究旨在探讨补充n-3多不饱和脂肪酸对糖尿病患者血清淫羊藿素水平的影响。这项随机临床试验包括43名2型糖尿病患者(安慰剂组21名患者和n-3多不饱和脂肪酸补充组22名患者)。他们被随机分为两组，一组接受n-3多不饱和脂肪酸补充剂10周，另一组接受安慰剂(1250毫克胶囊，每天三次)。两组的样本也在年龄、性别和体重指数(BMI)方面进行了匹配。干预前后均进行人体测量、人口学信息和膳食摄入量。采用人虹膜素酶联免疫吸附试验(ELISA)试剂盒检测干预前后的血清虹膜蛋白水平。用独立t检验比较两组间的平均结果。在基线时，安慰剂组和n-3多不饱和脂肪酸补充组之间的虹膜蛋白水平没有显著差异(P>；0.05)。干预后两组间差异有统计学意义(P=0.04)。平均变化(干预前后)差异有统计学意义(P=0.05)。与安慰剂相比，补充n-3多不饱和脂肪酸降低了血清FBS和HbA1C(P=0.036和0.001)。两组干预后舒张压和HOMA-IR的变化也有显著差异。病程没有被认为是一个混杂因素，因为在干预后和干预前的淫羊藿素水平与病程之间没有显著的关联。目前的研究表明，补充n-3多不饱和脂肪酸，剂量为1250 mg，每天三次，可导致糖尿病患者血清淫羊藿素水平升高。
Diabetes refers to a group of metabolic diseases with blood glucose of higher than normal ranges. Furthermore, n-3 polyunsaturated fatty acids are necessary for the regulation of the activity of human function. The effect of n-3 PUFA on diabetes has been investigated in animal studies, yet, the exact amount has not been set, to date. Irisin, as a new myokine, is released from skeletal muscle and Irisin levels decrease as a result of physical inactivity, overweightness, and obesity. Also, the reduction of serum irisin level is associated with development of insulin resistance and type 2 diabetes. This study was performed to assess the effects of n-3 PUFA supplementation on serum irisin level in patients with diabetes. This randomized clinical trial included 43 patients with type 2 diabetes (21 patients in the placebo group and 22 patients in the n-3 PUFA supplement group). They were randomized to groups, one receiving 10 weeks of either n-3 PUFA supplement and the other the placebo (1250 mg capsule, three times per day). Samples were also matched by age, gender, and body mass index (BMI) in the 2 groups. Anthropometric measurements, demographic information and dietary intakes were obtained both before and after the intervention. Serum irisin levels were measured before and after the intervention using human irisin enzyme linked immunosorbent assay (ELISA) kit. Independent t-test was used to compare the mean outcomes between groups. At baseline, irisin serum levels were not significantly different between the placebo and n-3 PUFA supplementation groups (P > 0.05). However, a significant change was observed between the groups after intervention (P = 0.04). Also there was a significant difference in mean change (after versus before the intervention) (P = 0.05). Compared to the placebo, n-3 PUFA supplementation decreased serum FBS and HbA1C (P = 0.036 and 0.001; respectively). Also, there were significant differences between changes of diastolic blood pressure and HOMA-IR after the intervention between the groups. The duration of illness was not considered as a confounding factor because there was no significant association between irisin level (after versus before the intervention) and the illness duration. The current study indicated that n-3 PUFA supplementation with a dosage of 1250 mg three times per day, resulted in increased serum irisin level of diabetic patients.